Dr. Daniela E. Matei, MD

Dr. Matei practices at Northwestern Memorial Hospital in Chicago, Illinois, part of Northwestern Memorial HealthCare.

Dr. Matei's NPI, 1558327486, was assigned on April 20, 2006. Dr. Matei holds Indiana license 01056559.

Dr. Matei's primary practice is Northwestern Memorial Hospital, at 251 E Huron St, Chicago, IL 60611 in Cook County. The practice phone is (312) 926-2000.

Dr. Matei's primary practice is Northwestern Memorial Hospital in Chicago, Illinois, part of Northwestern Memorial HealthCare. Dr. Matei is also affiliated with Northwestern Medicine Catherine Gratz Griffin Lake Forest Hospital. The medical group on file is Northwestern Medical Faculty Foundation. Dmand AI also links Dr. Matei to 1 more hospital, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Matei practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Matei's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Matei is licensed in Indiana.

CMS data shows 17,561 Medicare services from Dr. Matei across 15 procedure codes in 2024, for 118 Medicare patients. Medicare paid $48,900 for them. Every service was in an office.

CMS counts 118 Medicare patients who saw Dr. Matei in 2024. The largest group is 65 to 74, with 71 patients. 71% of them have high blood pressure, and 69% have cancer. 12% are also on Medicaid. Their average risk score is 2.16, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Matei's median patient age at 71, with 96% women.

In 2024, Dr. Matei wrote 49 Medicare Part D claims for 22 patients. 98% of them were for generic drugs. CMS names the drug for 13 of them, across 1 drug with 11 or more claims each, at $98 in total drug cost. In 2022, CMS named 11 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Matei for performance year 2024, reported through an alternative payment model (APM). Dr. Matei accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Matei as offering telehealth.

Dmand AI links 122 papers to Dr. Matei, published from 2006 to 2025. 2018 was the busiest year, with 13. The most frequent topics are Ovarian Neoplasms, Cell Line, Tumor and Antineoplastic Combined Chemotherapy Protocols. Dr. Matei has published most often in Gynecol Oncol. Dr. Matei's most frequent co-authors are Emma L. Barber, Gini F. Fleming and Yaqi Zhang, MD.

Dmand AI links Dr. Matei to 10 clinical trials, 6 of them phase 2 studies. 8 are still active or recruiting. Conditions studied include Fallopian Tube Diseases, Fallopian Tube Neoplasms and Carcinosarcoma. National Cancer Institute (NCI) sponsors the most, 6.

CMS Open Payments shows 79 general payments to Dr. Matei from 16 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 93% of the total. GlaxoSmithKline, LLC. paid the most, $28,835.